erastin
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00528047)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Ras GTPase-activating protein SynGAPINHIBITOR
SYNGAP1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- prlx 93936
- prlx 93936
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01695590 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2012 | Harvard University, Prolexys Pharmaceuticals |
| NCT00528047 | Phase 1 | Aug 1, 2007 | Harvard University, Prolexys Pharmaceuticals, TGen Drug Development, Tower Cancer Research Foundation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 2 | 0 | 2 | 2007 |
| Prolexys Pharmaceuticals | For profit | 2 | 2 | 2 | 2007 |
| TGen Drug Development | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Tower Cancer Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2007 |
4 organizations
Page 1 / 1